item management s discussion and analysis of financial condition and results of operations general medstone manufactures  markets and maintains lithotripters  and continues to expand its fee for service program to supply lithotripsy equipment to providers on a per procedure basis 
to date  the company s consolidated revenues have come primarily from medstone s lithotripsy business 
on february   the company distributed two stock dividends to stockholders of record on the close of trading on december  the two dividends represented distribution of all the assets and operations of the endocare and urogen divisions of the company 
effective with the start of business on january  these two companies were no longer a part of the medstone operations 
medstone retained  shares of each company 
these two companies are separate  publicly held companies 
in march  the company moved into a smaller  more efficient facility at a substantial cost saving 
this move did require a pma supplement to be filed with the fda and an audit from the fda 
the company received notification from the fda that the pma supplement was approved for manufacturing at the new facility 
the company as a manufacturer of capital medical devices has been vertically integrating by offering its medical devices directly to providers 
it currently offers lithotripsy procedures using mobile systems and one fixed site in the united states on a per procedure basis 
with the ability to offer quality equipment at reasonable prices  medstone intends to continue the growth of this manufacturer direct business 
in june  the company completed the acquisition of a interest in northern nevada  a lithotripsy partnership which deals directly with patient and insurers and also founded upr as a majority owned subsidiary of the company  to expand the company s service orientation to the urologist practitioner 
both entities signify the company s emphasis on growth through expansion of relationships and acquisition 
see also footnote to the company s consolidated financial statements regarding the recent acquisition of a interest in southern idaho lithotripsy associates  llc  another retail provider of lithotripsy services 
the company began the year with approximately million in cash and marketable securities  no debt  inventories of million  and total assets of million 
after an acquisition  settlement of the class action lawsuit  investment in seven new mobile trailers and one fixed site system  the company ended the year with approximately million in cash and marketable securities  no debt  inventories of million and total assets of million 
through its continuing research and development  management of the company is putting in place the scientific and engineering base it believes is necessary to carry it through the next phases of its growth plans 
the company was a defendant in two related class action lawsuits filed by two shareholders of the company alleging that adverse material information was not disclosed at the time of the initial public offering and in subsequent periods 
on june  the defendants and plaintiffs reached an agreement whereby a million  non recapturable settlement fund will be established in return for dismissal of all claims against the company  its underwriter and current and former officers and directors 
the company recorded a one time  million expense in the second quarter of to cover its portion of the settlement fund  with the first half paid on july  and the second half paid on august  all funds for the settlement were remitted by the company  with the co defendants paying their portions to the company 
see item legal proceedings 
from time to time  the company is subject to legal actions and claims for personal injuries or property damage related to patients who use its products 
the company has obtained a liability insurance policy providing coverage for product liability and other claims 
management does not believe that the resolution of any current proceedings will have a material financial impact on the company or the consolidated financial statements 
in  the company negotiated with coram healthcare coram for the right to purchase the lithotripsy related operations of coram 
in october  negotiations ceased and  upon coram s subsequent acquisition by integrated health services  inc  a breakup fee clause was enacted and the company is entitled to reimbursement of million of certain documented out of pocket expenses relating to the attempted acquisition and related financing 
the company is scheduled to receive the first reimbursement before the end of the first quarter of assets cash and equivalents and short term investments decreased by  at december  from december  due to the company s capital acquisitions  settlement of the class action lawsuit  and purchase of the northern nevada operation 
all of the company s invested cash balance is invested in us treasury bills at rates of to 
accounts receivable increased by  from december  to december  due to the addition of the northern nevada receivables and a much higher number of customers utilizing the fee for service program 
no receivables were written off against the accounts receivable reserves in inventories increased by  at december  from december  due to expansion of the company s manufacturing effort to meet delivery schedules of units to be shipped in early note receivable increased by  in the current year due to the company s reimbursement agreement from coram healthcare for certain expenses related to the company s bid to acquire the lithotripsy operations of coram 
prepaid expenses and other current assets decreased by  due to the company s shorter investment maturity schedule 
property and equipment increased by  from december  to december  primarily as a result of the purchase of mobile vans used in the mobile lithotripsy operations  partially offset by the distribution of the endocare and urogen assets 
goodwill  net  increased by  in the current year due to the purchase of northern nevada and the allocation of purchase price to the assets purchased 
other assets decreased by  in the current year due to last year s deposits for the manufacture of new mobile vans which were delivered in liabilities accounts payable at december  increased by  compared to december  due to expenses to be paid in connection with the company s attempted acquisition of the lithotripsy related operations of coram 
accrued income taxes increased  in the current year due to allocations between payables and deferred tax assets 
deferred revenue increased  in the current year due to prepayment of several years of maintenance and patient treatments by a new customer 
dividends payable at december  decreased by  due to the distribution of the stock dividend on february  of a share of common stock of both endocare and urogen for each share of the company held on december  deferred tax liabilities increased by  from december  to december  due to a difference between tax and book depreciation expense 
minority interest increased by  due to the acquisition in of northern nevada  of which the company is a owner 
stockholders equity additional paid in capital increased  in the current year due to the exercise of common stock options held by employees and associated tax benefits 
treasury stock increased by  due to the company s repurchase of  shares of its common stock under the repurchase program initiated in results of operations year ended december  compared to year ended december  total revenues decreased slightly to million  or for the year ended december  when compared to revenues of million in the year ended december  the revenues from equipment sales decreased by as both the number of units and the average unit selling price decreased 
also decreasing was the revenue from equipment upgrades when compared to revenue from procedure and maintenance fees  or recurring revenue  increased by million  or  from levels due to the company s continued success in its fee for service business  continued growth in revenue from procedure fees on third party owned equipment  and the addition of the northern nevada direct revenues 
volume on company owned mobile lithotripsy units increased by in when compared to procedure revenue increased by in when compared to as the volume on third party owned equipment continued to grow 
revenues acquired with northern nevada increase the per patient revenue due to the revenue recognized when billing patients or insurers when compared to the revenue from billing providers 
partially offsetting these gains was the loss of the endocare revenues  which totalled  in  which were spun out effective january  interest income decreased by in when compared to due to dramatically lower average invested cash balances which resulted from the large capital expenditures for mobile lithotripsy trailers and the settlement of the class action lawsuit 
cost of equipment sales in decreased by in from levels due to the lower number of unit shipments in the year 
gross margins on equipment and equipment upgrades decreased due to the decrease in average unit selling prices 
cost of recurring revenues increased by  or  in when compared to due to the additional costs associated with the eight additional fee for service vans placed in service in  which include depreciation  van movement costs  and staffing costs 
gross margins decreased due to lower than optimal utilization on the newer vans placed in service 
research and development costs decreased in by when compared to levels due to s level of expenses associated with numerous endocare new product development projects  most of which became salable new product lines before completion of the spinout of endocare 
in the company concentrated its research efforts on lithotripsy products 
selling expenses increased by  or  in when compared to due to the additional sales staff and associated expenses for travel  along with the costs of product brochures as the company expanded its mobile fee for service program from a western united states concentration to include the southwest  southeast and northeastern areas of the country 
the company also increased its efforts in connection with international sales in general and administrative expenses remained constant  with an increase of less than in compared to expenses 
administrative staff expenses of endocare  spun out at the end of  were offset by staff expenses for upr and northern nevada 
other income expense  net increased by  in when compared to due to the litigation preparation expenses for the class action litigation incurred before settlement of the action  partially offset by the gain on the sale of securities held for investment 
lawsuit settlement costs increased by million due to the expense recorded for the out of court settlement reached by the plaintiffs and defendants  of which the company was a co defendant  on the class action lawsuit that had been in existence since this settlement charge represents closure of all open charges against the company 
minority interest expense of  represents the minority shareholder s interest in the results of operations of northern nevada 
provision for benefit from income taxes recognizes the tax benefit in of the net operating loss carryforwards generated in with that carryforward expected to be utilized in future periods 
year ended december  compared to year ended december  total revenues increased to million for the year ended december   a increase from the revenues of million 
the increased net equipment sales resulted from an increase in both lithotripsy systems shipped  and an increase in the average lithotripter unit selling price 
this equipment revenue gain was slightly offset by a decline in of upgrades in the company s installed base of lithotripters from levels 
revenue from procedure and maintenance fees  or recurring revenue  increased in by 
million  or  from levels due to the continued expansion of the company s mobile lithotripsy services and increased revenue from the procedure fees on third party owned equipment offset by major declines in the laser catheter revenues 
revenues from mobile lithotripsy services increased by million or as the volume on the company s vans increased by in compared to the number of patients treated in procedure revenue increased by in as the utilization for the company s equipment owned by third parties continued to increase 
the number of procedures performed on third party owned lithotripters in the united states increased by from to several endocare product introductions in the fourth quarter of added  of revenues for offsetting these gains was a decrease in revenues from the laser catheters due to both lower unit shipments and prices  as this market matures 
interest income in increased by from levels due to increases in both average invested cash balances  due to higher cash flow from operations  and higher yields due to the interest rate increases as a result of market conditions 
cost of equipment sales in increased by from due to the increased number of unit shipments and the sale of higher cost van units 
gross margins on equipment and equipment upgrades decreased due to the combination of higher cost units and lower upgrade volume 
cost of recurring revenues increased in by  from due to the company s continued expansion of its mobile lithotripsy services and the requisite equipment investment and expenses related to their operations 
maintenance material costs increased by due to the higher number of units under contract 
research and development costs decreased in compared to the same period in due to the lower headcount associated with the refined research group 
selling expenses decreased in compared to the same period in the prior year  due to the decreased commission expenses for the lower laser catheter product sales and lower training expenses 
general and administrative expenses decreased in compared to the same period in due to the lower headcount and expenses relating to the scaled down endocare operation 
legal and other expenses increased primarily due to the expenses associated with the company s increased effort in preparation of defense of the class action lawsuit scheduled for trial in may the company s tax provision increased by million from to due to the booking in of deferred tax assets and the company providing for taxes at approximately statutory rates in liquidity and capital resources at december   the company had cash and short term investments of approximately million 
these funds were generated from operating activities and from the company s initial public offering in june the company s long term capital expenditure requirements will depend upon numerous factors  including the progress of the company s research and development programs  the time required to obtain regulatory approvals  the resources that the company devotes to the development of self funded products  proprietary manufacturing methods and advanced technologies  the cost of acquisition and or new revenue opportunities  the ability of the company to obtain additional licensing arrangements and to manufacture products under those arrangements  and the demand for its products if and when approved and possible acquisitions of products  technologies and companies 
the company believes that its existing working capital and funds anticipated to be generated from operations will be sufficient to meet the cash needs for continuation of its present operations during see safe harbor statement under the private securities litigation reform act of business acquisition as of march  the company has completed the acquisition of a interest in southern idaho lithotripsy associates  llc  an operator of a retail lithotripsy operation in southern idaho  for a purchase price of million in cash 
the assets  liabilities and operating results of southern idaho lithotripsy associates  llc will be consolidated effective march  safe harbor statement under the private securities litigation reform act of forward looking statements in this report  including without limitation  statements relating to the company s plans  strategies  objectives  expectations  intentions and adequacy of resources  are made pursuant to the safe harbor provisions of the private securities litigation reform act of investors are cautioned that such forward looking statements involve risks and uncertainties including without limitation the following i the company s plans  strategies  objections  expectations and intentions are subject to change at any time at the discretion of the company  ii the company s plans and results of operations will be affected by the company s ability to manage its growth  iii the company s businesses are highly competitive and the entrance of new competitors into or the expansion of the operations by existing competitors in the company s markets and other changes could adversely affect the company s plans and results of operations  and iv other risks and uncertainties indicated from time to time in the company s filings with the securities and exchange commission 

